NEW YORK, August 1, 2016 /PRNewswire/ --
The number of individuals who require medical attention and treatment is constantly growing, which is why Healthcare stocks remain in high demand. Earnings growth potential within the healthcare sector is much higher compared with other sectors, opening long-term opportunities for investors. Stock-Callers.com reviews the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Perrigo Co. PLC (NYSE: PRGO), and Lipocine Inc. (NASDAQ: LPCN). Learn more about these stocks by accessing their free research reports at:
Last Friday, Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock dropped 3.59%, to close the day at $22.30 with a total volume of 12.46 million shares traded. The Company's shares have advanced 10.01% in the last month. The stock is trading 7.00% below its 50-day moving average. Additionally, shares of Valeant Pharmaceuticals, which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide, have a Relative Strength Index (RSI) of 42.43.
On July 19th, 2016, Valeant Pharmaceuticals announced that the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S. Food and Drug Administration has voted by a margin of 18 to 0 for the approval of brodalumab injection, 210 mg, for adult patients with moderate-to-severe plaque psoriasis with conditions related to product labeling and post-marketing/risk management obligations. Free research report on VRX is available at:
Pernix Therapeutics Holdings
Shares in Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc. rose 3.10%, finishing the session at $0.59. The stock recorded a trading volume of 2.00 million shares. The Company's shares have gained 26.95% in the last month. The stock is trading above its 50-day moving average by 17.09%. Furthermore, shares of Pernix Therapeutics Holdings, which develops, manufactures, markets, and sells pharmaceutical products, have an RSI of 59.18.
On July 26th, 2016, Pernix Therapeutics Holdings announced a reorganization of the Company's senior management team. As part of the management change, John Sedor will assume the role of Chief Executive Officer on a permanent basis, and pharmaceutical industry veteran, Dr. Graham Miao, has been appointed as President and Chief Financial Officer. Dr. Miao will report directly to Mr. Sedor and will have responsibility for all functions related to finance, operations, regulatory and scientific affairs. The complimentary research report on PTX can be downloaded at:
Dublin, Ireland headquartered Perrigo Co. PLC's stock finished 0.34% higher at $91.39 last Friday at the close, with a total volume of 1.26 million shares traded. Shares of the Company, which together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide, are trading below their 50-day moving average by 3.60%. The stock has an RSI of 45.28.
On July 18th, 2016, Perrigo announced that the U.S. Food and Drug Administration has approved the company's ANDA for omeprazole and sodium bicarbonate capsules, 20mg/1100mg. This approval will initiate the first store brand launch of an equivalent product to Zegerid OTC® capsules. Zegerid OTC® is indicated for the treatment of frequent heartburn. National brand sales for the twelve months ending June 2016 were $27 million.
On July 22nd, 2016, research firm Deutsche Bank upgraded the Company's stock rating from 'Hold' to 'Buy', issuing a target price of $115 per share. Visit us today and access our complete research report on PRGO at:
Shares in Salt Lake City, Utah headquartered Lipocine Inc. last Friday's session 2.50% higher at $3.69 and with a total volume of 112,929 shares traded. The stock has advanced 19.03% in the last month. The Company's shares are trading 39.37% below their 50-day moving average. Moreover, shares of Lipocine, which develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health, have an RSI of 35.86.
On June 29th, 2016 Lipocine announced that it has received a Complete Response Letter from the FDA regarding its New Drug Application for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy. The CRL identified deficiencies related to the dosing algorithm for the label. Specifically, the proposed titration scheme for clinical practice was significantly different from the titration scheme used in the Phase 3 trial leading to discordance in titration decisions between the Phase 3 trial and real-world clinical practice. The next step will be to request a meeting with the FDA to understand fully the issues raised and to agree on a path forward to achieve approval of LPCN 1021.
On July 22nd, 2016, research firm ROTH Capital initiated a 'Buy' rating on the Company's stock, issuing a target price of $36 per share. Get free access to your research report on LPCN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA